Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Optimization of Tipranavir/Ritonavir in Experienced HIV Patients
NCT00275444Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2002
- Primary completion
- Jan 2003
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of tipranavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Virologic response after 2 weeks of functional monotherapy. Started Mar 2002; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00275444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275444.